Current patterns of care in low‐risk thyroid cancer—A national cross‐sectional survey of Australian thyroid clinicians

INTRODUCTION: De‐escalated treatment of hemithyroidectomy without radioactive iodine (RAI) is now accepted for patients with low‐risk, well‐differentiated thyroid cancer (WDTC). The benefit of long‐term follow‐up care remains controversial. This study aims to describe parameters associated with less than total thyroidectomy, and discharge from specialist follow‐up in patients with low‐risk WDTC in Australia. METHODS: An online survey was distributed to Australian members of Endocrine Society of Australia, Australian and New Zealand Endocrine Surgeons, and Australian Society of Otolaryngology, Head and Neck Surgery. Clinicians completed a survey of management and follow‐up care preferences for four clinical vignettes (all low‐risk WDTC). RESULTS: 119 clinicians (48% endocrinologists, 55% male) answered at least one question. The majority (59%) of respondents recommended less than total thyroidectomy and omission of RAI in patients with WDTC <2 cm. Most (62%) would discharge a patient with micropapillary thyroid cancer within 1 year following total thyroidectomy. In contrast, for WDTC 1–4 cm, >90% of clinicians would continue specialist follow‐up for at least 5 years. The majority of clinicians felt that patients experienced disproportionate fear of recurrence and were reassured by follow‐up. After multivariable analysis, clinicians who participated in multidisciplinary teams (MDTs) were more likely to choose de‐escalated care for both initial treatment (p = .005) and follow‐up care (>5 years, p = .05). CONCLUSION: Clinician attitudes captured by this survey reflect recent changes in guidelines towards hemithyroidectomy for low‐risk WDTC, particularly amongst MDT attendees. There is a need to further examine the impact of de‐escalated care on fear of recurrence and quality of life in thyroid cancer survivors.